Sermorelin vs CJC 1295 no DAC compared: half-life, dosing, GH pulses, side effects, and legal status. Learn which growth hormone peptide fits research needs.
Sermorelin and CJC-1295 no DAC are both growth hormone–releasing peptides that signal the pituitary to pulse out more growth hormone, but they are not interchangeable. The clearest difference is half-life: sermorelin clears in roughly 10 to 20 minutes, while CJC-1295 no DAC stays active for about 30 minutes because it resists enzymatic breakdown. Neither peptide is FDA-approved for general adult use, and neither is a proven treatment for any health condition.
What Sermorelin and CJC-1295 No DAC Actually Are
Sermorelin is the first 29 amino acids of human growth hormone–releasing hormone (GHRH), which is the same fragment the body produces on its own. It was once sold as a prescription drug called Geref for diagnostic testing of growth hormone deficiency in children, and that product is no longer marketed.
CJC-1295 no DAC — also written as CJC-1295 without DAC, mod GRF(1-29), or modified GRF 1-29 — is a synthetic analog of that same fragment. Four amino acid substitutions make it far more resistant to DPP-4, the enzyme that normally destroys natural GHRH within minutes.
- Sermorelin: native GHRH(1-29) sequence, short-acting, and the better studied of the two in humans.
- CJC-1295 no DAC: modified sequence, longer-acting, with very little controlled human trial data.
- CJC-1295 with DAC: the same peptide plus a drug affinity complex that binds albumin and extends half-life to days, which is a completely different profile.
Half-Life, Dosing, and Injection Frequency
Half-life drives nearly every practical difference between these two peptides. A shorter half-life means more frequent injections to sustain growth hormone pulses, while a longer half-life means fewer injections but a less natural release curve.
| Feature | Sermorelin | CJC-1295 No DAC |
|---|---|---|
| Half-life | About 10–20 minutes | About 30 minutes |
| Structure | Native GHRH fragment, 29 amino acids | Modified GHRH fragment, 4 substitutions |
| Typical research dose | 100–300 mcg per injection | 100–200 mcg per injection |
| Injection frequency in studies | 1–3 times daily | 1–2 times daily |
| Albumin binding (DAC) | No | No |
| FDA status for adults | Not approved; removed from the 503A bulks list | Not approved; sold as a research chemical |
| Common stack partner | Ipamorelin, GHRP-2 | Ipamorelin, GHRP-6 |
Typical research doses for sermorelin run 100 to 300 mcg, often split into two or three administrations. CJC-1295 no DAC is usually studied at 100 to 200 mcg once or twice per day. Anyone comparing cjc 1295 no dac vs sermorelin dosing charts will notice the numbers look similar — the real separator is how long each peptide stays active after the injection.
Growth Hormone and IGF-1 Effects
Both peptides act on the same GHRH receptor, so the downstream signal is identical: pituitary cells release growth hormone in pulses, and IGF-1 tends to rise over weeks of consistent use. Per microgram, CJC-1295 no DAC generally produces a larger GH response in animal and early human studies because it survives enzymatic breakdown longer.
Sermorelin has the deeper human safety record. Decades of pediatric diagnostic use give it a documented side-effect profile, which is more than can be said for most research peptides. That history does not make it effective for weight loss, anti-aging, or bodybuilding, and those claims come from marketing rather than evidence.
Individual responses to any GHRH peptide vary widely with age, body composition, sleep quality, and baseline IGF-1, so bloodwork matters far more than forum anecdotes.
Stacking: Ipamorelin, Tesamorelin, and DAC Versions
Most people searching sermorelin vs cjc-1295 no dac ipamorelin comparisons are looking at a two-pathway stack. GHRH analogs like sermorelin and CJC-1295 no DAC prime the pituitary, while ghrelin-receptor agonists like ipamorelin amplify the pulse. The two classes are complementary rather than redundant.
If you are weighing cjc-1295 no dac vs ipamorelin specifically, note that ipamorelin is a secretagogue and not a GHRH analog, so it belongs in a different column of the spreadsheet. It is also the most selective member of the GHRP family, which is why it appears in so many stack discussions.
Researchers interested in longer-acting options often compare tesamorelin vs cjc-1295 no dac. Tesamorelin is the only one of the three with an FDA approval — for visceral fat in people with HIV-associated lipodystrophy — which makes it a real drug rather than a research chemical. That approval came with a full clinical trial package, and it does not transfer to any other population.
The cjc-1295 dac vs no dac question matters here as well. DAC stands for drug affinity complex, and it binds the peptide to albumin, stretching the half-life from about 30 minutes to roughly 6 to 8 days. That produces sustained, non-pulsatile growth hormone elevation, which is the opposite of what most GHRH protocols are trying to achieve.
Side Effects, Safety, and Legal Status
Reported side effects for GHRH peptides include injection-site reactions, facial flushing, headache, dizziness, and mild water retention. CJC-1295 with DAC has been associated with prolonged IGF-1 elevation, and chronically high IGF-1 is linked to genuine health risks, including acromegaly-like changes in bone and soft tissue.
Regulatory status is the other hard limit. Neither sermorelin nor CJC-1295 no DAC is FDA-approved for human use in the United States. Sermorelin was removed from the FDA's 503A bulks list in 2023, which ended routine compounding by licensed pharmacies, and CJC-1295 has only ever been sold as a research chemical labeled "not for human consumption."
Both peptides are banned by WADA for athletes in competition. Anyone considering them should speak with a physician and get baseline IGF-1, glucose, and liver labs instead of relying on vendor claims.
The Bottom Line
Sermorelin is the shorter, naturally occurring fragment with the better documentation. CJC-1295 no DAC is the more potent, longer-lasting analog with far less human data behind it. For most research or clinical discussions, the choice comes down to how much human safety data you want versus how few injections you want to manage.
Frequently Asked Questions
Is CJC-1295 no DAC the same as sermorelin?
No. Sermorelin is the native first 29 amino acids of GHRH, while CJC-1295 no DAC is a synthetic version with four substitutions that make it resist breakdown by DPP-4. They act on the same receptor, but CJC-1295 no DAC stays active roughly two to three times longer. Neither is FDA-approved for general adult use.
Which is stronger, sermorelin or CJC-1295 no DAC?
Per microgram, CJC-1295 no DAC usually produces a stronger and longer growth hormone signal in studies because it is not degraded as quickly. Sermorelin is considered weaker and shorter-acting, but it has far more human safety data behind it. A stronger lab response does not mean a proven clinical benefit.
Is CJC-1295 no DAC or sermorelin FDA-approved?
Neither is FDA-approved for general adult use today. Sermorelin was previously marketed as the prescription drug Geref for pediatric diagnostic testing, but that product is discontinued, and the FDA removed sermorelin from the 503A compounding bulks list in 2023. CJC-1295 no DAC has never been approved and is sold only as a research chemical.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.